karpaka valli

karpaka valli


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Gopukumar S.TGopukumar S.T
Gopukumar S.T
DDDyumn Dwivedi
Dyumn Dwivedi
KGK. Gowri
K. Gowri
KVkarpaka valli
karpaka valli
CNChandralekha Nair
Chandralekha Nair
UDUddalak Das
Uddalak Das
Alzheimer's disease (AD), the predominant dementia etiology, imposes a $1.5 trillion global burden in 2025, exacerbated by inexorable failures in amyloid-tau-centric monotherapies amid <1% trial success rates. This review synthesizes cross-disciplinary pathobiology underpinning oncology drug repurposing for AD, leveraging inverse epidemiological antagonism and convergent hallmarks: aberrant neuronal cell-cycle re-entry (CDK5/p25, ERK-MAPK), proteostasis overload (HSP90-UPS-autophagy nexus), mTORC1 hyperactivation impairing lysosomal flux, kynurenine pathway (IDO1/TDO)-driven immunometabolic decoupling, PARP1-mediated NAD+ parthanatos, maladaptive neuroinflammation (PD-1/PD-L1 checkpoints, TAM-microglial skewing), and senescence-associated secretory phenotype (SASP)-amplified gliosis. Computational nomination pipelines—transcriptomic signature reversal (CMap/LINCS), network proximity in multi-omic knowledge graphs, and ligand-based docking—prioritize pleiotropic oncology agents: c-Abl/Src TKIs (nilotinib, bosutinib) enhancing autophagic Aβ/tau clearance; multikinase modulators (masitinib) resolving mast cell-microglial dyshomeostasis; rapalogs restoring proteostasis; IDO1 antagonists normalizing astrocytic lactate shuttling; PARPi mitigating genomic instability; HDACi reinstating synaptic epigenomes; and senolytics (dasatinib+quercetin) purging senescent glia. Phase I/II trials evince biomarker modulation (↓CSF p-tau, amyloid-PET; ↑autophagic flux) with geriatric-adapted dosing, yet underscore translational hurdles: BBB penetration, off-target liabilities, and polypharmacy in APOE ε4-enriched cohorts. A precision roadmap advocates orthogonal combinations (e.g., TKI+IDO1i), delivery-first PBPK modeling, and biomarker-anchored adaptive platforms to recalibrate AD's networked trajectory toward disease-modifying efficacy.

6 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Gopukumar S.TGopukumar S.T
Gopukumar S.T
MSMadhumita Saha
Madhumita Saha
PSPunniyamoorthy Sheela
Punniyamoorthy Sheela
PDPurbasha Das
Purbasha Das
MKM. Komala
M. Komala
Uddalak DasUddalak Das
Uddalak Das
Fungal ribosomally synthesized and post-translationally modified peptides (F-RiPPs) embody a paradoxical duality, transitioning from lethal mycotoxins to precision oncology payloads via antibody-drug conjugates (ADCs). This review portrays the biosynthetic logic of canonical families - amatoxins/phallotoxins, dikaritins, epichloëcyclins, and emergent asperigimycins, emphasizing PTMs like macrocyclization, N-methylation, and oxidative cross-links that confer proteolytic stability, membrane permeability, and target affinity. Genome mining pipelines integrating antiSMASH, seq2ripp, HypoRiPPAtlas, and GNPS molecular networking accelerate cryptic BGC decryption, heterologous expression in yeast/filamentous fungi, and combinatorial refactoring for analog libraries. Pharmacologically, F-RiPPs inhibit RNA Pol II (amatoxins), disrupt microtubules (dikaritins), perturb membranes (borosins), and induce lipid-mediated apoptosis (asperigimycins), with preclinical IC50s of 1–50 nM/μM and therapeutic indices >100 in xenografts. Translational exemplars include Heidelberg Pharma's ATACs, achieving Phase I/IIa remissions in myeloma/NHL via BCMA/CD37-targeted amanitin delivery. Addressing bottlenecks in silent cluster activation, enzyme mechanistics, and GMP-scaleup, a roadmap proposes ML-driven prioritization and automated heterologous platforms to harness untapped RiPP diversity for MDR-evasive, bystander-active therapeutics.

24 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Gopukumar S.TGopukumar S.T
Gopukumar S.T
DDDyumn Dwivedi
Dyumn Dwivedi
SMS. Muthumareeswari
S. Muthumareeswari
MRMohamed Rahamathulla
Mohamed Rahamathulla
MAMohammed Muqtader Ahmed
Mohammed Muqtader Ahmed
UDUddalak Das
Uddalak Das
Advances in single-cell and spatial multi-omics technologies have transformed the understanding of neutrophils from short-lived effector cells to highly heterogeneous and transcriptionally plastic immune populations. Within the inflamed intestinal microenvironment, gradients of cytokines, oxygen tension, and microbial metabolites such as short-chain fatty acids dynamically modulate neutrophil differentiation and function, shaping either tissue-protective or tissue-destructive phenotypes. Recent studies highlight the de novo expression of the NADPH oxidase enzyme DUOX2 in intestinal neutrophils as a pivotal mediator of redox signaling. DUOX2-derived reactive oxygen species activate epithelial and immune signaling cascades through NF-κB and p38 MAPK pathways, thereby amplifying inflammation, promoting barrier disruption, and sustaining microbial dysbiosis. Although this oxidative response enhances antimicrobial defense, it concurrently contributes to neutrophil extracellular trap (NET)-driven thrombo-inflammation and chronic tissue injury. Experimental evidence indicates that selective ablation of myeloid DUOX2 attenuates colitis, underscoring its potential as a therapeutic target. Emerging interventions that modulate this axis, including JAK/STAT inhibitors, CXCR2 antagonists, p38/MK2 inhibitors, and butyrate-based metabolic regulators, offer promising avenues to restore neutrophil homeostasis while maintaining host defense. Integrating single-cell transcriptomics, redox proteomics, and advanced imaging approaches will be essential for translating neutrophil plasticity into biomarker-guided and precision-based therapeutic strategies for durable mucosal healing in IBD.